No excess risk of adverse pregnancy outcomes among women with serological markers of previous infection with Coxiella burnetii: evidence from the Danish National Birth Cohort

BMC Infectious Diseases

Tine Brink Henriksen¹  Karen Angeliki Krogfelt⁶  Bjørn Kantsø³  Niels Henrik Hjøllund⁷  Kåre Mølbak⁵  Anne-Marie Nybo Andersen²  Stine Yde Nielsen⁴ 

[1] Perinatal Epidemiology Research Unit and Department of Pediatrics, Aarhus University Hospital, Brendstrupgaardsvej, Aarhus N, 8200, Denmark;Section of Social Medicine, Department of Public Health, University of Copenhagen, Oster Farimagsgade 5, Copenhagen, DK-1014, Denmark;Department of microbiology and infection control, Statens Serum Institut, Artillerivej 5, Copenhagen S, 2300, Denmark;Perinatal Epidemiology Research Unit, Aarhus University Hospital, Skejby, Brendstrupgaardsvej, Aarhus N, Denmark;Department of Infectious Disease Epidemiology, Statens Serum Institut, Artillerivej 5, Copenhagen S, 2300, Denmark;Department of microbiology and infection control, Statens Serum Institut, Artillerivej 5, Copenhagen S, 2300, Denmmark;Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

关键词: Preterm birth;    Spontaneous abortion;    Pregnancy;    Human;    Infection;    Coxiella burnetii;    Q fever;   

Others  :  1158389
DOI  :  10.1186/1471-2334-13-87

 received in 2012-09-18, accepted in 2013-02-14,  发布年份 2013

【 摘 要 】

Background

Q fever caused by Coxiella burnetii is transmitted to humans by inhalation of aerosols from animal birth products. Q fever in pregnancy is suspected to be a potential cause of fetal and maternal morbidity and fetal mortality but the pathogenesis is poorly understood, and even in Q fever endemic areas, the magnitude of a potential association is not established.

We aimed to examine if presence of antibodies to C. burnetii during pregnancy or seroconversion were associated with adverse pregnancy outcomes.

Methods

The Danish National Birth Cohort collected blood samples and interview data from 100,418 pregnant women (1996–2002). We sampled 397 pregnant women with occupational or domestic exposure to cattle or sheep and a random sample of 459 women with no animal exposure. Outcome measures were spontaneous abortion, preterm birth, birth weight and Small for Gestational Age (SGA).

Blood samples collected in pregnancy were screened for antibodies against C. burnetii by enzyme-linked immunosorbent assay (ELISA). Samples positive for IgG or IgM antibodies in the ELISA were confirmed by immunofluorescence antibody test (IFA).

Results

Among the 856 women, 169 (19.7%) women were IFA positive; 147 (87%) of these had occupational or domestic contact with livestock (IFA cutoff > =1:128).

Two abortions were IFA positive vs. 6 IFA negative (OR: 1.5; 95%CI: 0.3-7.6). Three preterm births were IFA positive vs. 38 IFA negative (OR: 0.4; 95% CI: 0.1-1.1). There was a significant difference in birth weight of 168 g (95% CI: 70-267 g) with IFA positive being heavier, and the risk of being SGA was not increased in the newborns of IFA positive women (OR: 0.4; 95%CI: 0.8-1.0).

Most seropositive women were IgG positive indicating previous exposure. Seroconversion during pregnancy was found in 10 women; they all delivered live babies at term, but two were SGA.

Conclusion

We found no increased risk of adverse pregnancy outcome in women with verified exposure to C. burnetii.

To our knowledge, this is the first population-based seroepidemiologic study evaluating pregnancy outcome in women with serologically verified exposure to C. burnetii against a comparable reference group of seronegative women.

【 授权许可】

   
2013 Nielsen et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Berri M, Rousset E, Champion JL, Russo P, Rodolakis A: Goats may experience reproductive failures and shed coxiella burnetii at two successive parturitions after a Q fever infection. Res Vet Sci 2007, 83(1):47-52.
• [2]Bildfell RJ, Thomson GW, Haines DM, McEwen BJ, Smart N: Coxiella burnetii infection is associated with placentitis in cases of bovine abortion. J Vet Diagn Invest 2000, 12(5):419-425.
• [3]Fournier PE, Marrie TJ, Raoult D: Diagnosis of Q fever. J Clin Microbiol 1998, 36(7):1823-1834.
• [4]Parker NR, Barralet JH, Bell AM: Q fever. Lancet 2006, 367(9511):679-688.
• [5]Tissot-Dupont H, Vaillant V, Rey S, Raoult D: Role of sex, age, previous valve lesion, and pregnancy in the clinical expression and outcome of Q fever after a large outbreak. Clin Infect Dis 2007, 44(2):232-237.
• [6]Agger JF, Christoffersen AB, Rattenborg E, Nielsen J, Agerholm JS: Prevalence of coxiella burnetii antibodies in Danish dairy herds. Acta Vet Scand 2010, 52:5. BioMed Central Full Text
• [7]Bacci S, Villumsen S, Valentiner-Branth P, Smith B, Krogfelt KA, Molbak K: Epidemiology and clinical features of human infection with coxiella burnetii in Denmark during 2006–07. Zoonoses Public Health 2011, 59(1):61-68.
• [8]Bosnjak E, Hvass AM, Villumsen S, Nielsen H: Emerging evidence for Q fever in humans in Denmark: role of contact with dairy cattle. Clin Microbiol Infect 2010, 16(8):1285-1288.
• [9]Carcopino X, Raoult D, Bretelle F, Boubli L, Stein A: Managing Q fever during pregnancy: the benefits of long-term cotrimoxazole therapy. Clin Infect Dis 2007, 45(5):548-555.
• [10]Carcopino X, Raoult D, Bretelle F, Boubli L, Stein A: Q fever during pregnancy: a cause of poor fetal and maternal outcome. Ann N Y Acad Sci 2009, 1166:79-89.
• [11]Raoult D, Fenollar F, Stein A: Q fever during pregnancy: diagnosis, treatment, and follow-up. Arch Intern Med 2002, 162(6):701-704.
• [12]Munster JM: Effectivenss of a screening program for Q fever during pregnancy: a clustered randomised controlled trial. Stockholm: Presentantion at the European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE); 2011. abstract
• [13]van der Hoek W, Meekelenkamp JC, Leenders AC, Wijers N, Notermans DW, Hukkelhoven CW: Antibodies against coxiella burnetii and pregnancy outcome during the 2007–2008 Q fever outbreaks in the Netherlands. BMC Infect Dis 2011, 11:44. BioMed Central Full Text
• [14]Olsen J, Melbye M, Olsen SF, Sorensen TI, Aaby P, Andersen AM, Taxbol D, Hansen KD, Juhl M, Schow TB, Sorensen HT, Andresen J, Mortensen EL, Olesen AW, Sondergaard C: The danish national birth cohort–its background, structure and aim. Scand J Public Health 2001, 29(4):300-307.
• [15]Marmion BP, Storm PA, Ayres JG, Semendric L, Mathews L, Winslow W, Turra M, Harris RJ: Long-term persistence of coxiella burnetii after acute primary Q fever. QJM 2005, 98(1):7-20.
• [16]Villumsen S, Jorgensen CS, Smith B, Uldum S, Schiellerup P, Krogfelt KA: Determination of new cutoff values for indirect immunofluorescence antibody test for Q fever diagnosis in Denmark. Diagn Microbiol Infect Dis 2009, 65(2):93-98.
• [17]Field PR, Mitchell JL, Santiago A, Dickeson DJ, Chan SW, Ho DW, Murphy AM, Cuzzubbo AJ, Devine PL: Comparison of a commercial enzyme-linked immunosorbent assay with immunofluorescence and complement fixation tests for detection of coxiella burnetii (Q fever) immunoglobulin M. J Clin Microbiol 2000, 38(4):1645-1647.
• [18]Kantso B, Svendsen CB, Jorgensen CS, Krogfelt KA: Comparison of two commercially available ELISA antibody test kits for detection of human antibodies against coxiella burnetii. Scand J Infect Dis 2012, 44(7):489-494.
• [19]Field PR, Santiago A, Chan SW, Patel DB, Dickeson D, Mitchell JL, Devine PL, Murphy AM: Evaluation of a novel commercial enzyme-linked immunosorbent assay detecting coxiella burnetii-specific immunoglobulin G for Q fever prevaccination screening and diagnosis. J Clin Microbiol 2002, 40(9):3526-3529.
• [20]Angelakis E, Raoult D: Q fever. Vet Microbiol 2010, 140(3–4):297-309.
• [21]Nielsen SY, Hjollund NH, Andersen AM, Henriksen TB, Kantso B, Krogfelt KA, Molbak K: Presence of antibodies against coxiella burnetii and risk of spontaneous abortion: a nested case–control study. PLoS One 2012, 7(2):e31909.
• [22]Whitney EA, Massung RF, Candee AJ, Ailes EC, Myers LM, Patterson NE, Berkelman RL: Seroepidemiologic and occupational risk survey for coxiella burnetii antibodies among US veterinarians. Clin Infect Dis 2009, 48(5):550-557.
• [23]Angelakis E, Million M, D’Amato F, Rouli L, Richet H, Stein A, Rolain JM, Raoult D: Q fever and pregnancy: disease, prevention, and strain specificity. Eur J Clin Microbiol Infect Dis 2012, 32(3):361-368.
• [24]Boden K, Brueckmann A, Wagner-Wiening C, Hermann B, Henning K, Junghanss T, Seidel T, Baier M, Straube E, Theegarten D: Maternofetal consequences of coxiella burnetii infection in pregnancy: a case series of two outbreaks. BMC Infect Dis 2012, 12(1):359. BioMed Central Full Text
• [25]van der Hoek W, Dijkstra F, Schimmer B, Schneeberger PM, Vellema P, Wijkmans C, ter Schegget R, Hackert V, van Duynhoven Y: Q fever in the Netherlands: an update on the epidemiology and control measures. Euro Surveill 2010, 15(12):19520.